Samba is an integrated drug discovery project that combines state-of-the-art molecular biology, informatics and medicinal chemistry methods to develop optimized pre-clinical candidates against alzheimer disease acting as inhibitors of bace-1 and acetylcholinesterase.
Development of kits and protocols for targeted next generation sequencing of 58 genes carrying potential deleterious mutations linked to breast/ovarian cancers and congenital myasthenic syndromes. Target-specific data analysis methods will be developed and validated for specificity and sensitivity.
Doxebo is a liposomal formulation jointly invented by the israeli and hungarian applicants. It reduces the risk of serious, occasionally lethal adverse effect of doxil and other similar nano-drugs. In this application we propose preclinical studies necessary for regulatory approval of doxebo.
The mission of the consortium is to utilize state-of-the-art pharmaceutical approaches and develop tnf-alpha-binding protein-imprinted polymers for the specific elimination of tnf-alpha from the gastrointestinal tract hence improving the therapy of currently untreatable crohn's disease.